GO! Astellas picks up partner in convertibleCAR for backloaded $780M antibody projectnews2022-06-01T10:43:44+00:00June 1st, 2022|FierceBiotech|
Bristol Myers Squibb, with new positive lupus data in hand, readies TYK2 inhibitor for final testnews2022-06-01T09:19:57+00:00June 1st, 2022|FierceBiotech|
After Axsome’s migraine med rejection, phase 3 data keeps hope alive for depression drugnews2022-05-31T14:44:33+00:00May 31st, 2022|FierceBiotech|
After Axsome’s migraine med rejection, phase 3 data keep hope alive for depression drugnews2022-05-31T14:44:33+00:00May 31st, 2022|FierceBiotech|
After oncology wind-down, TG’s pivot to MS faces setback as FDA pushes approval decisionnews2022-05-31T12:53:56+00:00May 31st, 2022|FierceBiotech|
Bouncing back from late-phase fail, Minoryx pockets €51M to guide rare disease drug to marketnews2022-05-31T12:22:48+00:00May 31st, 2022|FierceBiotech|
GSK strikes $3.3B Affinivax buyout to MAP out challenge to Pfizer’s blockbuster pneumococcal vaccinenews2022-05-31T09:20:01+00:00May 31st, 2022|FierceBiotech|
RhoVac’s prostate cancer vaccine phase 2 failure forces biotech to cut costsnews2022-05-30T10:52:39+00:00May 30th, 2022|FierceBiotech|
ASCO: Mirati cedes to Amgen’s Lumakras on durability in tight KRAS battlenews2022-05-27T13:05:08+00:00May 27th, 2022|FierceBiotech|
Addex’s eyelid data fail to make clear case for spasm expansionnews2022-05-27T11:43:12+00:00May 27th, 2022|FierceBiotech|
